

**NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE**

**TECHNOLOGY APPRAISAL PROGRAMME**

**Equality impact assessment – Scoping**

**STA Duvelisib for treating relapsed or refractory chronic lymphocytic leukaemia after at least 2 prior treatments**

The impact on equality has been assessed during this appraisal according to the principles of the NICE Equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

No potential equality issues have been identified during the scoping process.

2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?

Not applicable

3. Has any change to the draft scope been agreed to highlight potential equality issues?

Not applicable

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the matrix been made?

No additional stakeholders have been identified.

**Approved by Associate Director (name):** Ross Dent

**Date:** 22/07/2021

Technology Appraisals: Scoping  
Equality impact assessment for Single Technology Appraisal of Duvelisib for treating relapsed or refractory chronic lymphocytic leukaemia after at least 2 prior treatments  
Issue date: August 2021